Impact Biomedical (IBO) Non-Current Deferred Tax Liability (2022 - 2026)

Impact Biomedical (IBO) has reported Non-Current Deferred Tax Liability for 5 consecutive years, with $688000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non-Current Deferred Tax Liability fell 78.95% year-over-year to $688000.0; the trailing twelve-month figure through Jun 2026 stood at $688000.0 (down 78.95% YoY), and the FY2025 full-year result was $688000.0, down 86.4% from the prior year.
• Non-Current Deferred Tax Liability was little changed at $688000.0 in Q2 2026 per IBO's latest filing, from $688000.0 in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $5.1 million in Q4 2024 and bottomed at $688000.0 in Q4 2025.
• Historically, Non-Current Deferred Tax Liability has averaged $2.8 million across 5 years, with a median of $3.2 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Non-Current Deferred Tax Liability jumped 56.41% in 2024, then sank 86.4% in 2025.
• Over 5 years, Non-Current Deferred Tax Liability stood at $3.2 million in 2022, then changed by 0.0% to $3.2 million in 2023, then soared by 56.41% to $5.1 million in 2024, then tumbled by 86.4% to $688000.0 in 2025, then changed by 0.0% to $688000.0 in 2026.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $688000.0, $688000.0, and $688000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.